Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial | Zendy

Seung Cheol Shim | Zendy; Ljubinka Božić-Majstorović | Zendy; Alfredo Berrocal Kasay | Zendy; Elias Chalouhi El-Khouri | Zendy; Fedra Irazoque-Palazuelos | Zendy; Francisco Fidencio Cons Molina | Zendy; Francisco G. Medina-Rodriguez | Zendy; Pedro C. Miranda | Zendy; P. А. Shesternya | Zendy; José Chávez-Corrales | Zendy; Piotr Wiland | Zendy; Sławomir Jeka | Zendy; Olena Garmish | Zendy; Paweł Hrycaj | Zendy; Н. В. Фомина | Zendy; Won Park | Zendy; ChangHee Suh | Zendy; Sang Joon Lee | Zendy; Sungyoung Lee | Zendy; Yun Ju Bae | Zendy; DaeHyun Yoo | Zendy

Open Access

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

Author(s) -

Seung Cheol Shim,

Ljubinka Božić-Majstorović,

Alfredo Berrocal Kasay,

Elias Chalouhi El-Khouri,

Fedra Irazoque-Palazuelos,

Francisco Fidencio Cons Molina,

Francisco G. Medina-Rodriguez,

Pedro C. Miranda,

P. А. Shesternya,

José Chávez-Corrales,

Piotr Wiland,

Sławomir Jeka,

Olena Garmish,

Paweł Hrycaj,

Н. В. Фомина,

Won Park,

ChangHee Suh,

Sang Joon Lee,

Sungyoung Lee,

Yun Ju Bae,

DaeHyun Yoo

Publication year - 2019

Publication title -

lara d. veeken

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.957

H-Index - 173

eISSN - 1462-0332

pISSN - 1462-0324

DOI - 10.1093/rheumatology/kez152

Subject(s) - medicine , rituximab , biosimilar , rheumatoid arthritis , pharmacodynamics , rheumatology , immunogenicity , adverse effect , randomized controlled trial , gastroenterology , european union , immunology , antibody , pharmacokinetics , economic policy , business , lymphoma

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research